Objective: General practitioners (GPs) play a crucial role in human papillomavirus (HPV) vaccine acceptance in France. We sought to study: (1) GPs' perceptions of its risks and efficacy and their recommendation behavior; (2) the relative importance of factors associated with the frequency of their recommendations.
Methods: Cross-sectional observational study in 2014 nested in a national panel of 1712 randomly selected GPs in private practice in France (response rate: 92.4%). We used model averaging to analyze the associations of self-reported frequency of GPs' HPV vaccine recommendations with their perception of its risk-benefit balance and their opinions about the utility of vaccines in general.
Results: Overall, 72% of participants reported frequently recommending HPV vaccination; 60% considered that not enough is known about its risks. The model averaging showed that the factors most associated with infrequent recommendation of this vaccine by GPs were: unfavorable perceptions of its risk-benefit balance (OR=0.13; 95%CI=0.09-0.21; partial R(2)=0.10), a decision not to vaccinate one's own daughter(s) with this vaccine (OR=0.13; 95%CI=0.07-0.24; partial R(2)=0.05), and doubts about vaccine utility in general (OR=0.78; 95%CI=0.71-0.86; partial R(2)=0.03).
Conclusion: Although nearly three-quarters of French GPs frequently recommended the HPV vaccine, our findings indicate that a substantial percentage of them are hesitant about it. Doubts about its risks and efficacy strongly influence their recommendation behavior. More research is warranted to help design and evaluate tailored tools and multicomponent intervention strategies to address physician's hesitancy about this vaccine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2015.12.054 | DOI Listing |
Front Glob Womens Health
December 2024
Department of Nursing, College of Health Science, Woldia University, Woldia, Ethiopia.
Introduction: Human Papillomavirus (HPV) is a widespread sexually transmitted infection and a leading cause of cervical cancer. Although there is a significant HPV prevalence in Ethiopia, yet the uptake of the HPV vaccine remains low. This study aimed to assess the level of caregivers' willingness to vaccinate their daughters against the human papilloma virus and associated factors in Jimma town.
View Article and Find Full Text PDFVaccine
December 2024
TCD Biostatistics Unit, Discipline of Public Health and Primary Care, School of Medicine, Trinity College Dublin, Dublin, Ireland. Electronic address:
The safety and efficacy of vaccination is a subject contentious in the public mind. Despite overwhelming evidence of their benefits to public health, COVID-19 and human papilloma virus (HPV) vaccines have been the focus of intense concerns. While the original phase III trials and post-market phase IV studies have continued to show their benefits and positive safety profile, some authors have attempted to reassess the original trial data, purporting to showing hidden harms for both COVID-19 and HPV vaccines.
View Article and Find Full Text PDFJ Thorac Oncol
December 2024
Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA; Department of Medicine, University of California San Diego, La Jolla, CA 92037, USA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Introduction: Copy-number (CN) loss of chromosome 9p, or parts thereof, impair immune response and confer ICT resistance by direct elimination of immune-regulatory genes on this arm, notably IFNγ genes at 9p24.1, and type-I interferon (IFN-I) genes at 9p21.3.
View Article and Find Full Text PDFJ Clin Microbiol
December 2024
International Agency for Research on Cancer, Lyon, France.
Despite first-void urine (FVU) being increasingly recognized as a credible specimen for human papillomavirus (HPV) detection, there is a lack of well-validated testing methods providing full quantitative genotyping required for vaccine impact monitoring from FVU samples. The Allplex HPV28 assay, capable of individually detecting 28 HPV genotypes, presents a promising method. We aimed to evaluate its genotype-specific performance on FVU samples, following optimization of FVU preanalytics.
View Article and Find Full Text PDFJ Family Med Prim Care
November 2024
Department of Community Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, India.
To effectively prevent cervical cancer, a leading cause of global morbidity and mortality among women, widespread adoption of the HPV vaccine has a well-established link to human papillomavirus (HPV) infection. HPV vaccine must be the vaccine's effectiveness in reducing HPV infections, and subsequent cervical lesions have been extensively demonstrated, marking a pivotal milestone in public health. Important research highlights the vaccine's safety profile, allaying worries and promoting trust in its application.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!